# Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

> **NCT01864902** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed Adult Myeloid Leukemia
- Chemotherapy Refractory Adult Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CART33 cells
- **BIOLOGICAL:** anti-CD33 CART
- **BIOLOGICAL:** anti-CD33 CAR T cells

## Key facts

- **NCT ID:** NCT01864902
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2016-04
- **Final completion:** 2017-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2016-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864902, "Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01864902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*